Trial Profile
Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Corneal neovascularisation
- Focus Therapeutic Use
- 08 Nov 2019 Status changed from not yet recruiting to discontinued.
- 10 Nov 2015 New trial record